TDOCNYSEServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31
Teladoc Health, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$5.73+0.06 (+1.06%)
Close on Oct 19, 2026
- Market cap
- $1.04B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
69.5%+5.2 pts over 5 years
Operating margin
-10.4%+35.9 pts over 5 years
Net margin
-7.9%+36.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -1.5% | +1.7% | +18.3% | +41.7% | |
| Gross profit | -3.3% | +1.9% | +20.1% | +41.1% | |
| Free cash flow | +0.9% | +18.2% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -36.3% | -5.7% | -13.9% | |
| Return on assets | -27.8% | -5.0% | -6.3% | |
| Current ratio | 3.93 | 3.19 | 2.77 | |
| Interest coverage | – | – | -13.3× | |
| Inventory turnover | – | 13.8× | 20.2× | |
| Capex to revenue | 1.7% | 0.4% | 0.4% | |
| Diluted shares | 42M | 91M | 176M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Teladoc Health generated $1.32B from operations and spent $56.16M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.32B
Used
$56.16M
Capital expenditure$56.16M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-7.9%
×Asset turnover0.79×
×Equity multiplier2.22×
=Return on equity, FY2025-13.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -7.9% | 0.79× | 2.22× | -13.9% |
| FY2024 | -39.0% | 0.65× | 2.07× | -52.5% |
| FY2023 | -8.5% | 0.60× | 1.89× | -9.5% |
| FY2022 | -567.5% | 0.22× | 1.20× | -148.8% |
| FY2021 | -21.1% | 0.11× | 1.11× | -2.7% |
| FY2020 | -44.3% | 0.11× | 1.15× | -5.7% |
| FY2019 | -17.9% | 0.35× | 1.54× | -9.8% |
| FY2018 | -23.2% | 0.36× | 1.50× | -12.4% |
| FY2017 | -45.8% | 0.41× | 1.43× | -27.0% |
| FY2016 | -60.3% | 0.46× | 1.30× | -36.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$200.32M
- Cash generatingOperating cash flow above zero$294.36M
- Return on assets improvedROA up on the prior year-22.8% → -5.7%
- Earnings backed by cashOperating cash flow above net income$294.36M vs -$200.32M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.77 → 2.77
- No dilutionShare count did not rise171M → 176M
- Gross margin improvedGross margin up on the prior year70.76% → 69.50%
- More efficientAsset turnover rose0.59 → 0.72